Baseline characteristics of the cohort at time of diagnosis
| Baseline characteristic . | Total cohort (N = 247) . |
|---|---|
| Median age (range), y | 69 (24-89) |
| Percent male | 64.7 |
| IPSS-R risk stratification | |
| Very low | 15 (6.1) |
| Low | 36 (14.8) |
| Intermediate | 57 (23.4) |
| High | 51 (20.9) |
| Very high | 85 (34.8) |
| WHO classification | |
| MDS-SLD | 11 (4.4) |
| MDS-MLD | 52 (21.1) |
| MDS-RS-SLD | 2 (0.8) |
| MDS-RS-MLD | 14 (5.7) |
| MDS with isolated del(5q) | 2 (0.8) |
| MDS-EB1 | 59 (23.9) |
| MDS-EB2 | 63 (25.5) |
| MDS-U | 7 (2.8) |
| MDS/MPN | 16 (6.5) |
| AML (20%-30% blasts) | 21 (8.5) |
| Therapy-related myeloid neoplasm | 60 (24.3) |
| AML transformation | 81 (35.8) |
| First-line HMA therapy | |
| Azacitidine | 200 (81) |
| Decitabine | 29 (11.7) |
| HMA plus additional agent | 18 (7.3) |
| Proceeded to allo-HCT | 61 (24.7) |
| Patients with detectable mutation on NGS | 213 (86.2) |
| Median no. of mutated genes (range) | 2 (0-8) |
| Median absolute neutrophil count (range), × 109/L | 1.16 (0.06-28.8) |
| Median hemoglobin (range), g/dL | 9 (6.8-13.6) |
| Median platelet count (range), × 109/L | 64.5 (8-1073) |
| Median bone marrow blast percentage (range) | 8 (0-30) |
| Baseline characteristic . | Total cohort (N = 247) . |
|---|---|
| Median age (range), y | 69 (24-89) |
| Percent male | 64.7 |
| IPSS-R risk stratification | |
| Very low | 15 (6.1) |
| Low | 36 (14.8) |
| Intermediate | 57 (23.4) |
| High | 51 (20.9) |
| Very high | 85 (34.8) |
| WHO classification | |
| MDS-SLD | 11 (4.4) |
| MDS-MLD | 52 (21.1) |
| MDS-RS-SLD | 2 (0.8) |
| MDS-RS-MLD | 14 (5.7) |
| MDS with isolated del(5q) | 2 (0.8) |
| MDS-EB1 | 59 (23.9) |
| MDS-EB2 | 63 (25.5) |
| MDS-U | 7 (2.8) |
| MDS/MPN | 16 (6.5) |
| AML (20%-30% blasts) | 21 (8.5) |
| Therapy-related myeloid neoplasm | 60 (24.3) |
| AML transformation | 81 (35.8) |
| First-line HMA therapy | |
| Azacitidine | 200 (81) |
| Decitabine | 29 (11.7) |
| HMA plus additional agent | 18 (7.3) |
| Proceeded to allo-HCT | 61 (24.7) |
| Patients with detectable mutation on NGS | 213 (86.2) |
| Median no. of mutated genes (range) | 2 (0-8) |
| Median absolute neutrophil count (range), × 109/L | 1.16 (0.06-28.8) |
| Median hemoglobin (range), g/dL | 9 (6.8-13.6) |
| Median platelet count (range), × 109/L | 64.5 (8-1073) |
| Median bone marrow blast percentage (range) | 8 (0-30) |
Data are presented as n (%) unless otherwise specified.
MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; MDS-EB1, MDS with excess blasts-1; MDS-EB2, MDS with excess blasts-2; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts and multilineage dysplasia; MDS-RS-SLD, MDS with ring sideroblasts and single lineage dysplasia; MDS-SLD, MDS with single lineage dysplasia; MDS-U, MDS unclassifiable.